STOCK TITAN

[Form 4] KALA BIO, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

KALA BIO (KALA) reported an insider stock transaction on a Form 4. A director sold 47,768 shares of common stock on 10/22/2025 at a weighted average price of $0.83, with individual trades ranging from $0.82 to $0.85.

After the sale, the reporting person beneficially owned 35,932 shares directly, which includes 35,732 unvested RSUs, and 1 share indirectly held by a son.

KALA BIO (KALA) ha riportato una transazione insider su un Modulo 4. Un direttore ha venduto 47.768 azioni ordinarie il 22/10/2025 a un prezzo medio ponderato di 0,83 USD, con operazioni singole comprese tra 0,82 USD e 0,85 USD.

Después la vendita, la persona che presenta la relazione deteneva beneficiamente 35.932 azioni direttamente, che includono 35.732 RSU non vestite, e 1 azione indirettamente detenuta da un figlio.

KALA BIO (KALA) anunció una operación de insider en un Formulario 4. Un director vendió 47.768 acciones comunes el 22/10/2025 a un precio medio ponderado de 0,83 USD, con operaciones individuales que oscilaron entre 0,82 USD y 0,85 USD.

Después de la venta, la persona que reporta poseía beneficamente 35.932 acciones directamente, que incluyen 35.732 RSU no vestidas, y 1 acción indirectamente poseída por un hijo.

KALA BIO (KALA)는 Form 4에 따른 내부자 주식 거래를 보고했습니다. 이사는 2025년 10월 22일에 47,768주의 보통주를 매도했고, 가중 평균가 0.83달러를 기록했으며, 개별 거래는 0.82~0.85달러 범위였습니다.

매도 후, 보고자는 직접 35,932주의 주식을 보유하게 되었으며, 이 중 35,732주는 vesting되지 않은 RSU이고, 아들이 간접적으로 보유한 1주도 있습니다.

KALA BIO (KALA) a rapporté une transaction d’initié sur un formulaire 4. Un administrateur a vendu 47 768 actions ordinaires le 22/10/2025 à un prix moyen pondéré de 0,83 USD, avec des opérations individuelles allant de 0,82 USD à 0,85 USD.

Après la vente, la personne qui déclare détenait directement 35 932 actions, ce qui inclut 35 732 RSU non acquises, et 1 action détenue indirectement par un fils.

KALA BIO (KALA) meldete eine Insider-Aktientransaktion auf Formular 4. Ein Direktor verkaufte am 22.10.2025 47.768 Stammaktien zu einem gewichteten Durchschnittspreis von 0,83 USD, wobei einzelne Trades zwischen 0,82 USD und 0,85 USD lagen.

Nach dem Verkauf hielt die meldende Person direkt 35.932 Aktien, davon 35.732 RSU nicht vestet, und 1 Aktie indirekt von einem Sohn gehalten.

أعلنت Kala Bio (KALA) عن صفقة أسهم داخلية في نموذج 4. باع عضو مجلس إدارة 47,768 سهماً من الأسهم العادية في 22/10/2025 بسعر متوسط مرجح قدره 0.83 دولار، حيث تراوحت الصفقات الفردية بين 0.82 دولار و0.85 دولار.

بعد البيع، امتلك الشخص المبلغ عنه بشكل فعّال 35,932 سهماً مباشرة، والتي تشمل 35,732 RSU غير مكتسبة، و1 سهم مملوك بشكل غير مباشر لابنه.

Positive
  • None.
Negative
  • None.

KALA BIO (KALA) ha riportato una transazione insider su un Modulo 4. Un direttore ha venduto 47.768 azioni ordinarie il 22/10/2025 a un prezzo medio ponderato di 0,83 USD, con operazioni singole comprese tra 0,82 USD e 0,85 USD.

Después la vendita, la persona che presenta la relazione deteneva beneficiamente 35.932 azioni direttamente, che includono 35.732 RSU non vestite, e 1 azione indirettamente detenuta da un figlio.

KALA BIO (KALA) anunció una operación de insider en un Formulario 4. Un director vendió 47.768 acciones comunes el 22/10/2025 a un precio medio ponderado de 0,83 USD, con operaciones individuales que oscilaron entre 0,82 USD y 0,85 USD.

Después de la venta, la persona que reporta poseía beneficamente 35.932 acciones directamente, que incluyen 35.732 RSU no vestidas, y 1 acción indirectamente poseída por un hijo.

KALA BIO (KALA)는 Form 4에 따른 내부자 주식 거래를 보고했습니다. 이사는 2025년 10월 22일에 47,768주의 보통주를 매도했고, 가중 평균가 0.83달러를 기록했으며, 개별 거래는 0.82~0.85달러 범위였습니다.

매도 후, 보고자는 직접 35,932주의 주식을 보유하게 되었으며, 이 중 35,732주는 vesting되지 않은 RSU이고, 아들이 간접적으로 보유한 1주도 있습니다.

KALA BIO (KALA) a rapporté une transaction d’initié sur un formulaire 4. Un administrateur a vendu 47 768 actions ordinaires le 22/10/2025 à un prix moyen pondéré de 0,83 USD, avec des opérations individuelles allant de 0,82 USD à 0,85 USD.

Après la vente, la personne qui déclare détenait directement 35 932 actions, ce qui inclut 35 732 RSU non acquises, et 1 action détenue indirectement par un fils.

KALA BIO (KALA) meldete eine Insider-Aktientransaktion auf Formular 4. Ein Direktor verkaufte am 22.10.2025 47.768 Stammaktien zu einem gewichteten Durchschnittspreis von 0,83 USD, wobei einzelne Trades zwischen 0,82 USD und 0,85 USD lagen.

Nach dem Verkauf hielt die meldende Person direkt 35.932 Aktien, davon 35.732 RSU nicht vestet, und 1 Aktie indirekt von einem Sohn gehalten.

أعلنت Kala Bio (KALA) عن صفقة أسهم داخلية في نموذج 4. باع عضو مجلس إدارة 47,768 سهماً من الأسهم العادية في 22/10/2025 بسعر متوسط مرجح قدره 0.83 دولار، حيث تراوحت الصفقات الفردية بين 0.82 دولار و0.85 دولار.

بعد البيع، امتلك الشخص المبلغ عنه بشكل فعّال 35,932 سهماً مباشرة، والتي تشمل 35,732 RSU غير مكتسبة، و1 سهم مملوك بشكل غير مباشر لابنه.

KALA BIO(KALA) 在 Form 4 上披露了一笔内部人交易。董事于 2025-10-22加权平均价 0.83 美元 出售了 47,768 股普通股,单笔交易价格介于 0.82 美元至 0.85 美元 之间。

出售后,申报人直接持有 35,932 股,其中包含 35,732 股未归属的 RSU,以及由其儿子间接持有的 1 股

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bazemore Todd

(Last) (First) (Middle)
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 S 47,768 D $0.83(1) 35,932(2) D
Common Stock 1 I By son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
2. Includes 35,732 unvested RSUs.
/s/ Mary Reumuth, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

5.61M
6.06M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON